SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-012267
Filing Date
2022-06-28
Accepted
2022-06-28 16:16:07
Documents
12
Period of Report
2022-06-27
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K alna-20220627.htm   iXBRL 8-K 47145
  Complete submission text file 0000950170-22-012267.txt   170656

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT alna-20220627_lab.xml EX-101.LAB 14564
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT alna-20220627.xsd EX-101.SCH 2481
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT alna-20220627_pre.xml EX-101.PRE 10685
6 EXTRACTED XBRL INSTANCE DOCUMENT alna-20220627_htm.xml XML 5124
Mailing Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462
Business Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462 617-467-4577
Allena Pharmaceuticals, Inc. (Filer) CIK: 0001624658 (see all company filings)

IRS No.: 452729920 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38268 | Film No.: 221050317
SIC: 2836 Biological Products, (No Diagnostic Substances)